VEGFR2 antibody (Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase))

Details for Product anti-KDR Antibody No. ABIN967481, Supplier: Log in to see
Antigen
  • vegfr-2
  • KDR
  • 6130401C07
  • Flk-1
  • Flk1
  • Krd-1
  • Ly73
  • VEGFR-2
  • VEGFR2
  • sVEGFR-2
  • Vegfr-2
  • CD309
  • FLK1
  • VEGFR
  • FLK-1
  • flk-1
  • FLK/KDR
  • flk1
  • flk1b
  • kdrb
  • si:busm1-205d10.1
  • si:ch211-254j6.1
  • si:ch211-278f21.4
  • wu:fc31a09
  • fk52c05
  • flk
  • kdr
  • kdra
  • vegfr2
  • vegfr4
  • vegr2
  • wu:fk52c05
  • vascular endothelial growth factor receptor 2
  • kinase insert domain protein receptor
  • kinase insert domain receptor
  • kinase insert domain receptor (a type III receptor tyrosine kinase)
  • kinase insert domain receptor like
  • vascular endothelial growth factor receptor-2
  • vegfr-2
  • Kdr
  • KDR
  • kdr
  • kdrl
Alternatives
anti-Mouse (Murine) VEGFR2 antibody for Biochemical Assay
Reactivity
Mouse (Murine)
612
371
183
25
7
4
4
4
3
3
2
2
1
1
1
1
1
1
1
1
Host
Rat
535
141
59
4
2
2
1
Clonality (Clone)
Monoclonal ()
Conjugate
This VEGFR2 antibody is un-conjugated
45
32
24
20
18
12
11
9
9
5
5
5
5
4
4
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
1
1
Application
Flow Cytometry (FACS), Immunohistochemistry (IHC), Western Blotting (WB)
462
239
207
201
118
109
40
34
26
24
19
17
11
9
8
7
6
5
3
2
1
1
1
1
1
1
1
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Brand BD Pharmingen™
Immunogen Mouse Flk1 and human IgG1 fusion protein
Clone Avas 12alpha1
Isotype IgG2a, kappa
Characteristics 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Sodium azide is a reversible inhibitor of oxidative metabolism, therefore, antibody preparations containing this preservative agent must not be used in cell cultures nor injected into animals. Sodium azide may be removed by washing stained cells or plate-bound antibody or dialyzing soluble antibody in sodium azide-free buffer. Since endotoxin may also affect the results of functional studies, we recommend the NA/LE (No Azide/Low Endotoxin) antibody format, if available, for in vitro and in vivo use.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
Purification The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
Alternative Name Flk1 (KDR Antibody Abstract)
Background The Avas 12alpha1 antibody reacts with fetal liver kinase 1 (Flk-1), a receptor protein tyrosine kinase closely related to CD117 (c-kit) and CD140a (PDGF Receptor alpha chain) of the immunoglobulin superfamily. Flk-1, also known as VEGF Receptor-2 (VEGF-R2), is a receptor for vascular endothelial growth factor (VEGF). It is expressed, at the mRNA and protein levels, on distinct sets of mesoderm during gastrulation and on endothelial cells in embryonic tissues. In vivo and in vitro studies indicate that Flk-1 is required for the embryonic development of vascular endothelial and hematopoietic cells.
Synonyms: VEGF-R2, Ly-73
Pathways RTK Signaling, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity
Application Notes For immunohistochemistry application, we recommend to use purified Avas 12alpha1 mAb in our special formulation for immunohistochemistry.
Restrictions For Research Use only
Format Liquid
Concentration 0.5 mg/mL
Buffer Aqueous buffered solution containing ≤0.09 % sodium azide.
Preservative Sodium azide
Precaution of Use This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C
Storage Comment Store undiluted at 4° C.
Product cited in: Kataoka, Takakura, Nishikawa, Tsuchida, Kodama, Kunisada, Risau, Kita, Nishikawa: "Expressions of PDGF receptor alpha, c-Kit and Flk1 genes clustering in mouse chromosome 5 define distinct subsets of nascent mesodermal cells." in: Development, growth & differentiation, Vol. 39, Issue 6, pp. 729-40, 1998 (PubMed).

Nishikawa, Nishikawa, Hirashima, Matsuyoshi, Kodama: "Progressive lineage analysis by cell sorting and culture identifies FLK1+VE-cadherin+ cells at a diverging point of endothelial and hemopoietic lineages." in: Development (Cambridge, England), Vol. 125, Issue 9, pp. 1747-57, 1998 (PubMed).

Nishikawa, Nishikawa, Kawamoto, Yoshida, Kizumoto, Kataoka, Katsura: "In vitro generation of lymphohematopoietic cells from endothelial cells purified from murine embryos." in: Immunity, Vol. 8, Issue 6, pp. 761-9, 1998 (PubMed).

Hanahan: "Signaling vascular morphogenesis and maintenance." in: Science (New York, N.Y.), Vol. 277, Issue 5322, pp. 48-50, 1997 (PubMed).

Shalaby, Ho, Stanford, Fischer, Schuh, Schwartz, Bernstein, Rossant: "A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis." in: Cell, Vol. 89, Issue 6, pp. 981-90, 1997 (PubMed).

Shalaby, Rossant, Yamaguchi, Gertsenstein, Wu, Breitman, Schuh: "Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice." in: Nature, Vol. 376, Issue 6535, pp. 62-6, 1995 (PubMed).

Millauer, Wizigmann-Voos, Schnürch, Martinez, Møller, Risau, Ullrich: "High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis." in: Cell, Vol. 72, Issue 6, pp. 835-46, 1993 (PubMed).

Background publications Quinn, Peters, De Vries, Ferrara, Williams: "Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 90, Issue 16, pp. 7533-7, 1993 (PubMed).